JUBLPHARMA2023-10-012023-12-31 JUBLPHARMA2023-10-012023-12-31 JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member JUBLPHARMA2023-12-31 JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentRevenue01Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentRevenue02Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentRevenue03Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentRevenue04Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentRevenue05Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentRevenue06Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentRevenue07Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:FourReportableSegmentRevenue01Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:FourReportableSegmentRevenue02Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:FourReportableSegmentRevenue03Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:FourReportableSegmentRevenue04Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:FourReportableSegmentRevenue05Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:FourReportableSegmentRevenue06Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:FourReportableSegmentRevenue07Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentResults01Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentResults02Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentResults03Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentResults04Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentResults05Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentResults06Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentResults07Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:FourReportableSegmentResults01Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:FourReportableSegmentResults02Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:FourReportableSegmentResults03Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:FourReportableSegmentResults04Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:FourReportableSegmentResults05Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:FourReportableSegmentResults06Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:FourReportableSegmentResults07Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentAssets01Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentAssets02Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentAssets03Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentAssets04Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentAssets05Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentAssets06Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentAssets07Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentLiabilities01Member JUBLPHARMA2023-12-31in-bse-fin:OneReportableSegmentLiabilities01Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentLiabilities02Member JUBLPHARMA2023-12-31in-bse-fin:OneReportableSegmentLiabilities02Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentLiabilities03Member JUBLPHARMA2023-12-31in-bse-fin:OneReportableSegmentLiabilities03Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentLiabilities04Member JUBLPHARMA2023-12-31in-bse-fin:OneReportableSegmentLiabilities04Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentLiabilities05Member JUBLPHARMA2023-12-31in-bse-fin:OneReportableSegmentLiabilities05Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentLiabilities06Member JUBLPHARMA2023-12-31in-bse-fin:OneReportableSegmentLiabilities06Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneReportableSegmentLiabilities07Member JUBLPHARMA2023-12-31in-bse-fin:OneReportableSegmentLiabilities07Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member JUBLPHARMA2023-10-012023-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 530019 JUBLPHARMA NOTLISTED Jubilant Pharmova Limited Equity 2023-04-01 2024-03-31 2024-02-02 2024-01-23 INR Millions Third quarter 12:00:00 14:15:00 2024-02-02 2024-02-02 Not applicable Multi segment 2023-10-01 2023-12-31 Unaudited Consolidated 16771000000.00 358000000.00 17129000000.00 4315000000.00 718000000.00 326000000.00 5815000000.00 713000000.00 946000000.00 3417000000.00 16250000000.00 879000000.00 0.00 879000000.00 451000000.00 -105000000.00 346000000.00 0.00 533000000.00 0.00 0.00 0.00 131000000.00 664000000.00 170000000.00 834000000.00 668000000.00 -4000000.00 838000000.00 -4000000.00 158000000.00 1 4.22 4.20 0.00 0.00 4.22 4.20 Multi segment 2023-04-01 2023-12-31 Unaudited Consolidated 49443000000.00 543000000.00 49986000000.00 13240000000.00 1873000000.00 1020000000.00 16610000000.00 1993000000.00 2809000000.00 10406000000.00 47951000000.00 2035000000.00 0.00 2035000000.00 945000000.00 -48000000.00 897000000.00 0.00 1138000000.00 0.00 0.00 0.00 207000000.00 1345000000.00 610000000.00 1955000000.00 1357000000.00 -12000000.00 1968000000.00 -13000000.00 158000000.00 1 8.56 8.54 0.00 0.00 8.56 8.54 Other Expenses 3417000000.00 Other Expenses 10406000000.00 Allergy Immunotherapy 1724000000.00 Contract Development and Manufacturing Org. 3142000000.00 Contract Research, Development, and Manufacturing Org. 2635000000.00 Generics 1988000000.00 Proprietary Novel Drugs 0.00 Radiopharma 7522000000.00 Unallocable corporate 107000000.00 Allergy Immunotherapy 5041000000.00 Contract Development and Manufacturing Org. 9247000000.00 Contract Research, Development, and Manufacturing Org. 8493000000.00 Generics 5734000000.00 Proprietary Novel Drugs 0.00 Radiopharma 21837000000.00 Unallocable corporate 272000000.00 17118000000.00 50624000000.00 347000000.00 1181000000.00 16771000000.00 49443000000.00 Allergy Immunotherapy 604000000.00 Contract Development and Manufacturing Org. 174000000.00 Contract Research, Development, and Manufacturing Org. 224000000.00 Generics -524000000.00 Proprietary Novel Drugs -48000000.00 Radiopharma 1437000000.00 Unallocable corporate 0.00 Allergy Immunotherapy 1928000000.00 Contract Development and Manufacturing Org. 735000000.00 Contract Research, Development, and Manufacturing Org. 606000000.00 Generics -1647000000.00 Proprietary Novel Drugs -232000000.00 Radiopharma 3251000000.00 Unallocable corporate 0.00 1867000000.00 4641000000.00 713000000.00 1993000000.00 144000000.00 406000000.00 1010000000.00 2242000000.00 Allergy Immunotherapy 5314000000.00 Contract Development and Manufacturing Org. 31138000000.00 Contract Research, Development, and Manufacturing Org. 16057000000.00 Generics 17287000000.00 Proprietary Novel Drugs 2290000000.00 Radiopharma 28523000000.00 Unallocable corporate 0.00 100609000000.00 12658000000.00 113267000000.00 Allergy Immunotherapy 551000000.00 Contract Development and Manufacturing Org. 7937000000.00 Contract Research, Development, and Manufacturing Org. 2320000000.00 Generics 2616000000.00 Proprietary Novel Drugs 159000000.00 Radiopharma 6453000000.00 Unallocable corporate 0.00 20036000000.00 38360000000.00 58396000000.00 Items that will not be reclassified to profit and loss -7000000.00 Items that will not be reclassified to profit and loss 36000000.00 -7000000.00 36000000.00 -3000000.00 -7000000.00 Items that will be reclassified to profit and loss 174000000.00 Items that will be reclassified to profit and loss 567000000.00 174000000.00 567000000.00 0.00 0.00